<DOC>
	<DOCNO>NCT00570817</DOCNO>
	<brief_summary>Infusions high-dose methotrexate 5 g/m2 8 g/m2 use treat child acute lymphoblastic leukemia ( ALL ) , non-Hodgkin 's lymphoma , medulloblastoma ependymoma . Methotrexate primarily excrete unchanged kidney course acute kidney damage result prolonged time excretion drug . Our main hypothesis 12 hour intravenous hydration methotrexate infusion efficacious prevent methotrexate induce kidney damage compare four hour hydration .</brief_summary>
	<brief_title>Prevention Methotrexate Induced Nephrotoxicity Prolonged Drug Elimination Time With 12 Hours Prehydration</brief_title>
	<detailed_description>Infusions high-dose methotrexate 5 g/m2 8 g/m2 accord protocol Nordic Association Pediatric Hematology Oncology 2000 ( NOPHO-2000 ) use treat child acute lymphoblastic leukemia ( ALL ) . Treatment methotrexate 5 g/m2 also use treat child non-Hodgkin lymphoma , medulloblastoma ependymoma . Methotrexate primarily excrete unchanged kidney course acute nephrotoxicity result prolonged elimination time drug . Data 10 year retrospective investigation pediatric unit show , spite urine alkalinization intensive hydration elimination methotrexate prolong 20-50 % infusion . The long exposure high serum methotrexate concentration associate increased frequency mucositis bone marrow suppression . Further need rescue folic acid problematic , possibly result high risk relapse ALL ( Leukemia 2006 ; Skarby TV ) . Most ALL protocol prescribe prehydration 2-6 hour initiation methotrexate infusion never investigate randomize control trail longer time prehydration prevent nephrotoxicity reduce risk prolong elimination . In pediatric unit prehydration give rate 150 ml/m2/hour solution 5 % glucose 40 mmol sodium bicarbonate/L 20 mmol potassium chloride/L . Our main hypothesis 12 hour prehydration efficacious prevent methotrexate induce nephrotoxicity compare four hour prehydration . A child enrol study half methotrexate infusion receive 12 hour prehydration half receive four hour prehydration .</detailed_description>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Age 1 21 year diagnosis ALL Treatment highdose methotrexate 5 g/m2 8 g/m2 accord protocol `` Nordic Association Pediatric Hematology Oncology 2000 ( NOPHO2000 ) '' new protocol ( NOPHO2008 ) enrolment begin approx . January 2009 . Treatment highdose methotrexate 5 g/m2 accord protocol `` Treatment Protocol TCell BPrecursor Cell Lymphoblastic Lymphoma 2002 European Intergroup Cooperation Childhood NonHodgkinLymphoma ( EICNHL ) '' Treatment medulloblastoma ependymoma highdose methotrexate 5 g/m2 accord protocol : `` ( HIT2000 ) Hirntumorprotokoll der Hrbeitsgruppe f체r Hirntumoren '' Deutsche Gesellschaft f체r P채diatrische Onkologie und H채matologie ( GPOH ) . Patient parent willing give consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Nephrotoxicity</keyword>
	<keyword>Hydration</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Medulloblastoma</keyword>
	<keyword>Ependymoma</keyword>
	<keyword>Prolonged elimination time methotrexate</keyword>
</DOC>